Inhibitory GABA A receptor modulators are widely used therapeutic agents for a variety of central nervous system disorders. Ltk Ϫ cells stably expressing human recombinant GABA A subunits (␣1␤1-3␥2s) were seeded into 96-well plates, loaded with chlorocoumarin-2-dimyristoyl phosphatidylethanolamine and bis(1,3-diethyl-2-thiobarbiturate)trimethineoxonol, and rapid fluorescence resonance energy transfer technique (FRET) measurements were made of GABA-evoked depolarizations in lowCl Ϫ buffer using a voltage/ion probe reader. The influence of different ␤ subunits on the ability of agents to modulate and directly activate the ion channel was examined. GABA evoked concentration-dependent decreases in FRET, increasing fluorescence emission ratio (460/580 nm) at ␣1␤1␥2, ␣1␤2␥2, and ␣1␤3␥2 receptors with similar maximal amplitude (P Ͼ 0.05, n ϭ 17) and EC 50 values of 2.4 Ϯ 0.2, 2.5 Ϯ 0.2, and 1.3 Ϯ 0.1 M, respectively. Piperidine-4-sulfonic acid and 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol were less potent, with EC 50 values of 8.7 Ϯ 0.9, 9.2 Ϯ 0.5, and 11.7 Ϯ 1.2, and 43.7 Ϯ 6.4, 24.8 Ϯ 1.6, and 26.1 Ϯ 2.4 M, respectively. Potency and maximal efficacy of propofol, methyl 6,7-dimethoxy-4-ethyl-␤-carboline-3-carboxylate, pentobarbital, and steroids, 5␣-pregnan-3␣-ol-20-one and 5␤-pregnan-3␣-ol-20-one, were unaffected by the ␤ isoform present in the receptor complex. However, several compounds displayed ␤2/3 subunit selectivity, notably loreclezole, R(Ϫ)-etomidate, and a group of antiinflammatory agents including mefenamic acid, flufenamic acid, meclofenamic acid, tolfenamic acid, niflumic acid, and diflunisal. The anti-inflammatories exhibited varying levels of efficacy at ␤2/3 subunits, with micromolar potency, while having antagonist or weak inverse agonist profiles at ␣1␤1␥2. Diflunisal was the most efficacious compound, eliciting greater potentiation than loreclezole (90 Ϯ 14% and 109 Ϯ 14% at ␤3 and ␤2, respectively, compared with 62 Ϯ 6% and 56 Ϯ 3%), whereas niflumic acid exhibited the lowest efficacy. An additional agent, olsalazine, weakly potentiated responses at all three receptors without any selectivity. This study identifies and characterizes a variety of allosteric modulators for which ␤ subunits are an important determinant of efficacy and potency.
GABA is the predominant inhibitory neurotransmitter in mammalian central nervous system, and ligand-gated GABA A receptor ion channels are the target for a wide range of therapeutic agents including benzodiazepines, barbiturates, steroids, convulsants, and anesthetics (reviewed in Mehta and Ticku, 1999) . GABA A receptors are pentameric assemblies of multiple subunits (␣1-6, ␤1-3, ␥1-3, ␦, ⑀, , and ; Whiting et al., 1999) with an integral chloride channel and a variety of allosteric binding sites through which rapid inhibitory synaptic neurotransmission can be modulated. Subunit assembly and stoichiometry studies have revealed a variety of receptor subunit combinations that are differentially expressed in mammalian brain (Fritschy and Mohler, 1995; McKernan and Whiting, 1996) , with the most abundant receptor subtypes generally having a 2␣:2␤:1␥ stoichiometry . Multiple subunits provide the potential for enormous structural diversity, although evidence suggests differential assembly signals within ␣ and ␤ subunits operate to restrict the number of possible combinations (Bollan et al., 2002) . The largest GABA A receptor population in rat brain has an ␣1␤2␥2 composition, whereas ␣2␤3␥2 and ␣3␤␥2/␥3 together constitute the next most prevalent subtypes (McKernan and Whiting, 1996) .
The precise array of subunits present in the receptor complex governs the pharmacological and functional properties of receptor subtypes. The GABA agonist binding site is thought to occur at the interface of ␣ and ␤ subunits (Ebert et al., 1997) , whereas affinity and efficacy at the well-characterized benzodiazepine site are influenced by residues in both ␣ and ␥ (Wingrove et al., 1997) but not ␤ (Hadingham et al., 1993) subunits. The ␤ subunit variant has been shown to influence loreclezole and etomidate sensitivity, with a single amino acid at the carboxyl-terminal end of the putative channel-lining domain TM2, being a key determinant of selectivity Belleli et al., 1997) . More recently, it has also been suggested that the ␤ subunit plays a dominant role in determining the ion selectivity of heteromeric GABA A receptors (Jensen et al., 2002) .
Several groups have described regional localization of different ␤ subunits in rat brain (Wisden et al., 1992; Miralles et al., 1999; Pirker et al., 2000) . All ␤ subunits are widely distributed throughout the brain, although ␤2 is the most abundant, especially in cerebellum and cortex, and immunoreactivity is also highly concentrated in thalamic nuclei with the exception of the reticular nucleus. In hippocampus, ␤3 is the most abundant of the ␤ subunits, but some interneurons express high levels of ␤2, and there is some ␤1 expression on both dendrites and interneurons. There are high levels of ␤3 expression, with little ␤2, in corpus striatum and in the granule cells of the olfactory bulb, whereas in the cerebellum, ␤2 and ␤3 subunits predominate over ␤1.
Given the wide diversity of GABA A receptor subtypes, often in distinct neuronal circuits, and the variety of allosteric sites on the receptor through which ion channel activity can be subtly modulated, specificity is clearly key to the development of novel compounds for this therapeutic target. Progress has recently been made in dissecting functional roles of different GABA A receptors using knockout and point mutation strategies (Rudolph et al., 2001 ). Evidence to date supports the notion that subunit-selective modulators may elicit desirable clinical efficacy with reduced side effects, one such example being at the benzodiazepine site where it is possible to separate anxiolysis and sedation, each being mediated via different GABA A ␣-subunits (McKernan et al., 2000) . Identification of such compounds that can discriminate between GABA A receptor subunits requires a functional assay with sufficiently high sensitivity to detect subtle modulation of ion channel activity.
In the present study, we have utilized a rapid ratiometric, voltage-sensitive fluorescence resonance energy transfer technique (FRET) (Gonzalez et al., 1999) to measure GABAevoked changes in membrane potential. Using this approach, we have characterized the influence that different ␤ subunits exert on the pharmacological modulation of GABA A receptor ion channels.
Materials and Methods
Cell Culture. Combinations of human GABA A receptor subunits (␣1␤x␥2s) were stably expressed in mouse Ltk Ϫ fibroblast cells by transfection of the appropriate subunit cDNAs in vector pMSGneo using standard calcium phosphate transfection techniques. Cells, passaged weekly, were maintained at 37°C in Dulbecco's modified Eagle's medium (DMEM) (Invitrogen, Carlsbad, CA), supplemented with 10% (v/v) FetalClone II serum (Hyclone) and 1 mg/ml geneticin. For experiments, cells were removed from stock plates with 0.05% trypsin/0.53 mM EDTA solution (Invitrogen) and resuspended in DMEM supplemented with 10% FetalClone II serum but without geneticin. Cells were seeded into black-sided Porvair 96-well microtiter plates at densities of 3 to 8 ϫ 10 4 cells/ml in a volume of 200 l/well and grown in the presence of 10% serum for 5 to 8 days in an incubator at 37°C. Receptor expression, which is under the control of a dexamethasone-sensitive promoter, was induced 24 h prior to experiment in the confluent cell monolayers using serum-containing DMEM supplemented with 1 M dexamethasone (Sigma Chemical, Poole, Dorset, UK). Fluorescence Measurement of Membrane Potential. Experiments were performed, as previously described , in low-Cl Ϫ buffer (160 mM sodium-D-gluconate, 4.5 mM potassium-D-gluconate, 2 mM CaCl 2 , 1 mM MgCl 2 , 10 mM D-glucose, and 10 mM HEPES, pH 7.4). Cells were washed twice, leaving 35 l of residual volume, and 65 l of dyes were added to give final concentrations of 4 M chlorocoumarin-2-dimyristoyl phosphatidylethanolamine (CC2-DMPE; FRET donor) and 1 M bis(1,3-diethyl-2-thiobarbiturate)trimethineoxonol [DiSBAC 2 (3); FRET acceptor]. Cells were dyeloaded for 30 min at room temperature in darkness, washed again, and dye solutions were then added to give a final concentration of 1 M DiSBAC 2 (3) with 0.5 mM tartrazine to quench extracellular fluorescence. Plate preparation was automated using a CCS Packard Platetrak.
Plates were then placed in a voltage/ion probe reader (Aurora Biosciences Corp., San Diego, CA), which performs automated additions using a Hamilton 2200 pipetter and records fluorescence emissions at 460 and 580 nm simultaneously from eight wells (Gonzalez et al., 1999) . A 400DF15 filter was used in the excitation pathway and 460DF45 and 580DF60 filters in the respective emission pathways. Rapid ratiometric FRET measurements were made of GABAevoked depolarizations in low-Cl Ϫ buffer, and the ability of compounds to modulate an EC 50 response to GABA was examined. Experiments were performed using a two-addition protocol whereby basal fluorescence was read for 8 s before addition of test compounds, and a half-maximal concentration of GABA was added 22 s later, with fluorescence emissions recorded at 1 Hz. For assessment of the direct effect of compounds on channel opening, the initial addition was buffer only, and test compound alone was added as a second addition.
Data Analysis. Data were analyzed as previously described . For each time point at each fluorescence emission wavelength, background fluorescence was subtracted (recorded from wells without cells in the same plate), and the ratio of fluorescence at 460 to 580 nm was calculated. GABA-evoked depolarizations were then expressed as a fractional change in this ratio, with the mean plateau ratio taken between 10 and 15 s after GABA addition normalized to the mean ratio over the first 6 s of recording before agonist addition. Algorithms written as Excel 97 (Microsoft, Redmond, WA) macros were used for automated calculations of fluorescence ratio, and GABA responses and concentration response curves were fitted to a four-parameter logistic equation using Prism (Prism version 2.0b; GraphPad Software Inc., San Diego, CA). Effects of compounds were expressed as percent change in the EC 50 GABA response in the presence of compound versus the EC 50 response alone, determined in control wells on the same plate.
Agonist stimulation and modulatory responses were assessed by performing one-way analysis of variance using Prism version 2.0b (GraphPad Software Inc.) followed by post hoc testing using Tukey's multiple comparison test to determine significance. Mean EC 50 , IC 50 , and efficacy values are presented as the arithmetic mean and S.E.M. from a number of independent and separate determinations (n), typically with at least four replicate test wells per concentration point on each plate tested.
Materials. CC2-DMPE was obtained from Aurora Biosciences Corp., DiSBAC 2 (3) was from Molecular Probes (Eugene, OR), and tartrazine was obtained from Sigma. GABA, 4, 5, 6, pyridin-3-ol (THIP), piperidine-4-sulfonic acid (P4S), gluconate salts, and all other GABA A receptor modulators were also from Sigma. 2,6-diisopropylphenol (propofol) was from Aldrich, and etomidate was obtained from Janssen Pharmaceuticals (Antwerp, 
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Belgium) as Hypnomidate, 2 mg/ml injectable solution. S(Ϫ)-Etomidate was synthesized in-house.
Results

GABA Site Ligands.
Under low-chloride conditions, GABA evoked concentration-dependent depolarizations in cells loaded with CC2-DMPE and DisBac 2 (3) and expressing GABA A receptors of composition ␣1␤1␥2s, ␣1␤2␥2s, or ␣1␤3␥2s. These depolarizations were rapidly transduced into decreased FRET and, therefore, an increase in the ratio of fluorescence emission at 460 nm (f460) to that at 580 nm (f580). The fluorescence emission ratio rose to a concentration-dependent plateau within 5 s and was sustained for more than 15 s (Fig. 1) . Agonist responses at each receptor subtype were of similar maximal amplitude (P Ͼ 0.05; oneway analysis of variance followed by post hoc Tukey test), although GABA exhibited slightly higher potency at ␤3-containing receptors (P Ͻ 0.001) ( Table 1 ) compared with ␤2 and ␤1.
Other GABA site ligands also evoked concentration-dependent decreases in FRET. P4S and THIP exhibited lower potency than GABA and, in addition, P4S exhibited reduced efficacy compared with the maximum GABA response (P Ͻ 0.01; n ϭ 4) ( Table 2) . THIP, however, did not exhibit significantly different efficacy compared with maximum GABA.
Influence of ␤ Subunit on Modulation of the GABA Response. The ability of compounds to modulate the response to GABA was examined using an equieffective concentration of GABA (EC 50 ), predetermined for each receptor subtype. As previously reported (Hadingham et al., 1993) , benzodiazepine site ligands did not discriminate between receptor isoforms containing different ␤ subunits. At the maximal concentration tested (10 M), the inverse agonist methyl 6,7-dimethoxy-4-ethyl-␤-carboline-3-carboxylate negatively modulated GABA responses at ␣1␤1␥2, ␣1␤2␥2, and ␣1␤3␥2 receptors, with maximal efficacies of Ϫ48 Ϯ 4% (n ϭ 5), Ϫ42 Ϯ 6% (n ϭ 5), and Ϫ42 Ϯ 6% (n ϭ 3), respectively (Fig. 2) . In contrast, the anticonvulsant loreclezole exhibited subtype selectivity, with quantitatively greater maximal efficacy and potency at ␤2-and ␤3-versus ␤1-containing receptors (Fig. 2) . There was little potentiation of ␣1␤1␥2 receptors up to 10 M (15 Ϯ 4%, n ϭ 7), whereas ␣1␤2␥2 and ␣1␤3␥2 receptor responses were potentiated by 56 Ϯ 3% (n ϭ 7) and 62 Ϯ 6% (n ϭ 4), respectively, with EC 50 values of 1.9 and 0.6 M. Neither compound elicited any direct activation of the receptor in the absence of GABA.
Modulation and Activation of ␣ 1 ␤ x ␥ 2s GABA A Receptors by Anesthetics, Steroids, and Anti-Inflammatory Agents. The i.v. anesthetic propofol (Fig. 3A) and the nonvolatile anesthetic barbiturate pentobarbital (Fig. 3B) potentiated the EC 50 GABA response at all receptor subtypes. The maximal efficacies and potencies for propofol were not significantly different for ␤1-, ␤2-, and ␤3-containing receptors, being 123 Ϯ 21, 132 Ϯ 29, and 128 Ϯ 24% and 3.8 Ϯ 1.2, 2.4 Ϯ 0.6, and 1.6 Ϯ 0.1 M, respectively (P Ͼ 0.05; n ϭ 5). Pentobarbital was approximately an order of magnitude less potent than propofol, with EC 50 values of 22.6 Ϯ 2.3, 22.0 Ϯ 1.9, and 13.4 Ϯ 2.5 M, and maximal efficacies of 133 Ϯ 29, 168 Ϯ 26, and 140 Ϯ 41%, respectively (n ϭ 3). Both propofol and pentobarbital directly activated the ion channel in the absence of GABA at concentrations approximately 10-fold higher than those eliciting potentiation of the GABA response (EC 50 values of 27.2 Ϯ 2.0, 25.3 Ϯ 1.7, and 20.3 Ϯ 3.0 M, n ϭ 6 -9; and 119 Ϯ 7.5, 117 Ϯ 15.9, and 75 Ϯ 3.0 M, n ϭ 3-6, respectively). For all compounds where a significant direct effect of the compound on the ion channel in the absence of GABA was observed, the modulation effects shown represent the total effect of the compound, given the absence of tools to block this direct component. Thus, for pentobarbital, at concentrations above 100 M, a significant portion of the modulatory effect is likely to be due to a direct effect on the channel itself.
The anesthetic agent etomidate similarly both potentiated the EC 50 GABA response and, at higher concentrations, caused direct activation (Fig. 4A) . Like loreclezole, etomidate also displayed functional selectivity for ␤2/␤3 subunits over ␤1, having both increased potency (EC 50 values 0.5 Ϯ 0.1 and 0.3 Ϯ 0.1 M, respectively) and higher maximal efficacy (152 Ϯ 20 and 158 Ϯ 23% potentiation, respectively) than at ␣1␤1␥2 receptors (EC 50 2.9 Ϯ 0.8 M; efficacy 107 Ϯ 19%; n ϭ 4). Etomidate evoked a higher degree of potentiation of the GABA response than loreclezole at all three subunit combinations examined. Unlike loreclezole, etomidate elic- ited direct effects on GABA A receptors, and this direct activation of the ion channel at higher concentrations also displayed ␤ subunit selectivity (n ϭ 6). Etomidate exhibited enantiomeric selectivity, with the S(ϩ)-enantiomer displaying reduced potency and no ␤ subunit selectivity (Fig. 4B) , in contrast to the R(Ϫ)-enantiomer (Fig. 4A) . The S(ϩ)-enantiomer could not be tested at high enough concentrations to determine whether there was any direct activation. The steroid pharmacology of these GABA A receptor isoforms was also investigated. The progesterone metabolite 5␣-pregnan-3␣-ol-20-one, together with 5␣-pregnan-3␤-ol-20-one and 5␤-pregnan-3␣-ol-20-one, were all tested for their ability to modulate ion channel opening (Fig. 5) . 5␣-Pregnan-3␣-ol-20-one robustly potentiated GABA responses and did not discriminate between different ␤ subunits, eliciting quantitatively similar maximal efficacies at all receptors with little difference in potency (Fig. 5a) . In contrast, 5␣-pregnan-3␤-ol-20-one had no significant effect on the GABA response except at the top concentration (200 M) where there was a modest inhibition (␤1, Ϫ18 Ϯ 4%; ␤2, Ϫ38 Ϯ 7%; ␤3, Ϫ35 Ϯ 8%; n ϭ 9) (Fig. 5b) . 5␤-Pregnan-3␣-ol-20-one elicited potentiation of all three receptor subtypes with similar potency and maximal efficacy (Fig. 5c) .
A group of nonsteroidal anti-inflammatory agents were also examined for modulatory and direct effects on GABA A receptors (chemical structures shown in Fig. 6 ). The aminoarylcarboxylic acid derivatives mefenamic acid, flufenamic acid, meclofenamic acid, tolfenamic acid, and niflumic acid and the salicylic acid derivatives diflunisal and olsalazine all showed activity at GABA A receptors. Except for olsalazine, the anti-inflammatories all selectively potentiated ␣1␤2␥2s and ␣1␤3␥2s receptors, exhibiting varying levels of efficacy at ␤2/3 subunits, with micromolar potency, while having antagonist or weak inverse agonist profiles at ␣1␤1␥2. The ability of compounds to modulate the EC 50 response to GABA is shown in Table 3 . Diflunisal was the most efficacious of these compounds, eliciting greater potentiation than loreclezole (90 Ϯ 14 and 109 Ϯ 14% at ␤3 and ␤2, respectively, compared with 62 Ϯ 6 and 56 Ϯ 3%), although it was an order of magnitude less potent. Niflumic acid exhibited the lowest efficacy. The aminoarylcarboxylic acid derivatives were more potent modulators than the salicylic acid derivatives. An additional agent, olsalazine, weakly potentiated responses at all three receptors without any selectivity and elicited some direct activation at the top concentration tested (200 M). There was no direct receptor activation observed up to 200 M with niflumic acid or flufenamic acid, a very modest direct effect at the top concentration with mefenamic acid and diflunisal, whereas a more robust direct effect was observed for meclofenamic ( Fig. 7) and tolfenamic (Fig. 8) acids.
Discussion
In this study, we have performed the most comprehensive study yet undertaken of the effect of ␤ subunit expression on the activation and modulation of GABA A receptor subtypes. We demonstrate the importance of ␤ subunits in influencing the action of a variety of agents, highlighted by the marked differences in efficacy and potency of loreclezole, etomidate, and multiple nonsteroidal anti-inflammatory agents, the GABA A receptor selectivity of some of which are reported here for the first time. An earlier study examining GABAevoked currents recorded in oocytes expressing rat cortex mRNA (Woodward et al., 1994) was the first to suggest that some anti-inflammatory agents had the potential to modulate GABA A receptors, although the precise receptor subunit composition was unclear, and there was no information about receptor selectivity. Many of the compounds displaying subunit selectivity are used clinically, and it will be interesting to explore further whether differences in their efficacy profiles underlie some of their distinct physiological effects.
Evidence suggests that nonsteroidal anti-inflammatories can effectively cross the blood-brain barrier (Bannwarth et al., 1989) . This, together with the relatively high therapeutic plasma concentrations that are achieved in the region of 80 M and 20 to 70 M for mefenamic and niflumic acids, respectively (Halliwell et al., 1999; Sinkkonen et al., 2003) , suggests that appreciable brain levels might be achieved. Indeed, observations of antiepileptogenic effects (Wallenstein, 1991) and adverse events associated with anti-inflammatory overdose are consistent with activity at central GABA A receptors. Given that low micromolar concentrations are sufficient to potentiate ␤2/3-containing GABA A receptors, this suggests that modulatory effects could occur at clinically relevant concentrations. In addition, the anti-inflammatorysensitive ␣1␤2␥2 receptor subtype is the largest GABA A receptor population in mammalian brain (McKernan and Whiting, 1996) . As well as activity at GABA A receptor ion channels, fenamate nonsteroidal anti-inflammatories have also been reported to have activity at a variety of other ion channels (e.g., Greenwood and Large, 1995; Malykhina et al., 2002) .
Application of FRET techniques to the study of GABA A receptors has been previously described . Clearly, in terms of agonist time course, these FRET responses have a slower onset than those determined by more direct electrophysiological measures of channel opening, with peak currents attained within 5 s versus millisecond responses using patch-clamp techniques. Although the GABA response is likely to occur rapidly, changes in FRET are downstream of this and, thus, are a slower readout of channel function. The current technique is influenced by the speed of voltage-dependent redistribution DiSBAC 2 (3) in the membrane, which occurs subsequent to the flow of chloride ions and membrane depolarization. However, potency values obtained using voltage/ion probe reader fluorescence measurements for GABA-evoked depolarizations and allosteric modulation at a variety of GABA A receptors agree well with values reported from other assays including electrophysiology (e.g., Wafford et al., 1994; Smith et al., 2001 ). In addition, this technique offers the potential for much increased throughput, allowing scope to more widely explore the pharmacology of different recombinant receptors.
Recent studies of murine ␤3 homomeric GABA A ion channels indicate these GABA-insensitive receptors can still respond to pentobarbital, propofol, etomidate, and pregnanolone (Wooltorton et al., 1997) , although the properties of murine ␤1 homomers are somewhat different. This appears to be due to a single amino acid, asparagine-265, at the extracellular end of M2 (Cestari et al., 2000) , the same residue that regulates potentiation by etomidate (Belleli et al., 1997) but not pentobarbital in heteromeric receptors. This amino acid has also been implicated in the action of Fig. 3 . The potencies and efficacies for potentiation of the GABA EC 50 response and direct channel gating by the i.v. anesthetic propofol (A) and the barbiturate pentobarbital (B) were not markedly affected by the ␤ isoform present in the receptor complex. Propofol (n ϭ 5 determinations) was an order of magnitude more potent than pentobarbital (n ϭ 3 determinations) in potentiating GABA. Both compounds elicited direct channel activation at all subtypes at concentrations approximately 10-fold higher than those that potentiated GABA (n ϭ 3 determinations each). The modulation graph represents the total effect of the compounds. and mediates potentiation by high concentrations of ␤-carbolines (Stevenson et al., 1995) . Although the presence of a ␤2 or ␤3 subunit is clearly a prerequisite for loreclezole efficacy, different ␣ or ␥ subunits reportedly influence the level of potentiation . In a detailed study of one particular anti-inflam- Fig. 4 . The anesthetic agent R(Ϫ)-etomidate exhibited higher potency and efficacy for potentiation of GABA responses at receptors containing a ␤2 or a ␤3 subunit (mean Ϯ S.E.M. from four independent experiments) and also elicited direct ion channel activation at higher concentrations (n ϭ 6), potency and efficacy being reduced at ␤1-containing receptors (A); etomidate also exhibited stereoselectivity with the S(ϩ)-enantiomer displaying lower potency and no subunit selectivity (B). matory agent at different recombinant receptors (Halliwell et al., 1999) , the same residue was also implicated in ␤ subunitselective modulation of GABA A receptors by mefenamic acid. Additionally, Sinkkonen et al. (2003) reported that potentiation of ␣1␤2␥2 receptors by niflumic acid depended on the presence of a ␥2 subunit, also found to influence mefenamic acid modulation (Halliwell et al., 1999) . Antagonism of the ␣6␤2␥2 receptor subtype by niflumic acid has also been reported (Sinkkonen et al., 2003) , and substitution of an ␣4 subunit reduced mefenamic potentiation of ␣1␤2␥2 receptors by 50% (Whittemore et al., 1996) .
Pentobarbital, propofol, and etomidate all elicited quantitatively larger potentiations of the GABA response than loreclezole, anti-inflammatories, and steroids. Although the nature of the ␤ subunit is clearly critical for both potentiation and GABA-mimetic activity of etomidate, with lower potency and efficacy evident for ␤1-containing receptors, the actions of propofol, pentobarbital, and steroids were found in our study to be similar irrespective of the ␤ isoform present in the receptor complex. However, evidence for direct involvement of ␤ subunit residues in the action of propofol comes from a study showing that methionine 286 in transmembrane domain 3 of the ␤ subunit controlled a binding cavity for propofol (Krasowski et al., 2001) and was implicated in potentiation of GABA responses but not in direct activation. This may imply the two phenomena are mediated via separate sites, a view supported by Siegwart et al. (2002) , who observed differential structural requirements for modulatory and direct effects of a variety of general anesthetics. There is also evidence that a glycine residue at the entrance to TM1 of the ␤2 subunit is involved in channel gating and anesthetic modulation (Carlson et al., 2000) . In the current study, pentobarbital, etomidate, and propofol all had pronounced effects on direct activation at approximately 10-fold higher concentrations than those which potentiated the GABA response.
With regard to pentobarbital, the affinity of potentiation electrophysiologically in oocytes was little affected by altering ␣ or ␤ subunits, although the maximal degree of potentiation was influenced by the nature of the former but not the latter (Thompson et al., 1996) , in agreement with the present results. With regard to direct activation by pentobarbital, the ␣ subunit influenced both the affinity and efficacy of the direct effect, whereas the nature of the ␤ subunit exerted a lesser influence on these parameters, only showing differ- ences when coexpressed with ␣1 but not with ␣6. This is in contrast to the current observations and may reflect celltype-specific differences. Although the ␤ subunit appears to have little impact on the action of steroids, it clearly plays a role in mediating their effects since modulation is preserved even at homomeric ␤ subunit-containing receptors (Wooltorton et al., 1997) . Many compounds examined in the present study showed evidence of declining responses at high concentrations (e.g., Figs. 3, a and b, 4a, 7, and 8) , and this was evident both for modulatory and direct effects. Similar observations have been made in electrophysiological studies of the action of pentobarbital, etomidate, and mefenamic acid (Thompson et al., 1996; Belleli et al., 1997; Halliwell et al., 1999) . Previous studies have identified several different effects with respect to the action of anesthetic agents: a potentiation of the GABA response, direct activation of the ion channel, and, at higher concentrations, a block of the GABA chloride channel. It is likely, at higher concentrations of test agents, that multiple processes may be occurring simultaneously that may limit the amount of potentiation that can be observed.
Etomidate showed stereoselectivity in potentiating GABA responses, with the S(Ϫ)-enantiomer exhibiting lower potency and no ␤ subunit selectivity, unlike the R(ϩ)-enantiomer. Stereoselectivity has also been reported for steroids with multiple chiral centers (Covey et al., 2000) . The latter study indicates that 5␣-reduced steroids show a much higher degree of enantiospecificity in their actions as modulators and as anesthetics than 5␤-reduced steroids. The limited effect here of 5␣-pregnan-3␤-ol-20-one agrees with previous published data describing the stereoselectivity of the 3-hydroxy group, which must be in the ␣ configuration for potent receptor modulation (El-Etr et al., 1998; Hawkinson et al., 1998) .
An additional compound which is a derivative of salicylic acid, salicylidene salicylhydrazide, has recently been reported by us to also display ␤ subunit selectivity (Thompson et al., 2004) , being a selective inhibitor of ␤1-containing receptors. This further supports the finding that ␤ subunits are an important determinant of efficacy and potency for a variety of allosteric modulators and direct activators of human GABA A receptor ion channels. In the current study, we have used a novel fluorescence technique that provides rapid and sensitive measurements of GABA A receptor function to examine the influence of differing ␤ subunit expression on the potency and efficacy of a variety of ligands. Several compounds discriminated ␤2/␤3 from ␤1-containing receptors including the anticonvulsant loreclezole, the anesthetic etomidate, and a relatively diverse group of anti-inflammatory agents. Fig. 7 . The nonsteroidal anti-inflammatory agent meclofenamic acid selectively potentiated ␣1␤2␥2s and ␣1␤3␥2s receptors with similar potency and similar maximal efficacy, while displaying inverse agonism at ␤1 (n ϭ 7 determinations). There was some direct activation with this compound at concentrations approximately 10-fold higher than those at which potentiation was observed (n ϭ 4 determinations). 
